Brief: Dicot Pharma Gets FDA Clearance To Start First Part Of Phase 2B Study With Lib-01 In U.S.
25/06/2026 08:43
BRIEF-Dicot Pharma Gets FDA Clearance To Start First Part Of Phase 2B Study With Lib-01 In U.S. June 25 (Reuters) - Dicot Pharma AB DICOT.ST:
RECEIVES FDA CLEARANCE TO INITIATE THE FIRST PART OF THE PHASE 2B STUDY WITH LIB-01 IN THE U.S.
APPLICATION TO COMMENCE STUDY IN EUROPE WILL BE SUBMITTED TO RELEVANT REGULATORY AUTHORITIES IN Q3
STUDY IS EXPECTED TO START IN SECOND HALF OF 2026, IN LINE WITH PREVIOUSLY COMMUNICATED TIMELINE
Source text: ID:nMFN1tF420
Further company coverage: DICOT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Dicot Pharma AB
See all newsBrief: Dicot Pharma Recruits Cecilia Driving As CFO
Brief: Dicot Pharma Gets FDA Clearance To Start First Part Of Phase 2B Study With Lib-01 In U.S.
Brief: Dicot Pharma Announces Outcome In Oversubscribed Rights Issue
Brief: Dicot Pharma Announces Prelim Rights Issue Outcome
Brief: Dicot Pharma Submits IND Application To FDA